Linked Data API

Show Search Form

Search Results

1131321
registered interest false more like this
date less than 2019-06-11more like thismore than 2019-06-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what progress he has made on ensuring that medical cannabis is available to people who need it. more like this
tabling member constituency Birkenhead remove filter
tabling member printed
Frank Field more like this
uin 263063 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2019-06-19more like thismore than 2019-06-19
answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients.</p><p>Interim clinical guidance has been issued by the Royal College of Physicians, the British Paediatric Neurology Association and the Association of British Neurologists to support doctors looking to prescribe cannabis-based products. The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of cannabis-based medicinal products, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-19T14:21:18.483Zmore like thismore than 2019-06-19T14:21:18.483Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
478
label Biography information for Lord Field of Birkenhead more like this
1128815
registered interest false more like this
date less than 2019-06-03more like thismore than 2019-06-03
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that all patients who would benefit from medical cannabis are able to access that treatment on prescription on the NHS. more like this
tabling member constituency Birkenhead remove filter
tabling member printed
Frank Field more like this
uin 259011 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2019-06-11more like thismore than 2019-06-11
answer text <p>Cannabis-based products for medicinal use are no different from other medicines, and existing systems for the funding of both licensed and unlicensed medicines apply.</p><p>Any medicines which receive a marketing authorisation from the Medicines and Healthcare Products Regulatory Agency or European Medicines Agency will be assessed for cost effectiveness by the National Institute for Health and Care Excellence. This is the foundation of National Health Service decisions about routine funding, and applies to all licensed medicines. For unlicensed medicines, the normal NHS medicines governance systems apply, as they do to all locally funded unlicensed treatments. These processes support good clinical practice and safe and effective prescribing. Decisions will be taken, at NHS Trust level on a case by case basis, based on the needs of the individual patient and the evidence of efficacy and cost effectiveness available.</p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care has heard patients report difficulties in accessing medicinal cannabis. As a result, he asked the Department to work closely with NHS England to undertake a rapid process evaluation. This is underway and will review NHS system processes to identify and make recommendations to address any barriers to clinically appropriate prescribing, should they exist.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-11T16:52:22.153Zmore like thismore than 2019-06-11T16:52:22.153Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
478
label Biography information for Lord Field of Birkenhead more like this
1063970
registered interest false more like this
date less than 2019-02-19more like thismore than 2019-02-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps he is taking to prevent patients from being incorrectly denied access to medicinal cannabis. more like this
tabling member constituency Birkenhead remove filter
tabling member printed
Frank Field more like this
uin 223142 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2019-02-27more like thismore than 2019-02-27
answer text <p>The decision to prescribe a cannabis-based product for medicinal use is one for individual clinicians to make, as part of a multidisciplinary team and in partnership with patients and their families.</p><p> </p><p>It would be inappropriate to second-guess the prescribing decisions of clinicians, who will be experts in their area and bear responsibility for prescribing.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2019-02-27T16:19:18.873Zmore like thismore than 2019-02-27T16:19:18.873Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
478
label Biography information for Lord Field of Birkenhead more like this
1005764
registered interest false more like this
date less than 2018-11-12more like thismore than 2018-11-12
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NHS and medical professional body guidelines on the prescription of medicinal cannabis in ensuring the eligibility for prescription of patients for whom that treatment might be advantageous. more like this
tabling member constituency Birkenhead remove filter
tabling member printed
Frank Field more like this
uin 190361 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-11-15more like thismore than 2018-11-15
answer text <p>The Medical Director of NHS England, Professor Steve Powis, and the Chief Medical Officer, Professor Dame Sally Davies, have written to relevant clinicians to coincide with the coming into force of the rescheduling of cannabis-based medicinal products. The guidance in this letter, which signposts interim clinical advice commissioned from the British Paediatric Neurology Association and the Royal College of Physicians, is in line with normal clinical practice. The decision to prescribe cannabis-based products for medicinal use will be made on a case-by-case basis, based on clinical need and in-line with existing governance procedures for prescribing unlicensed medicines.</p><p> </p><p>The Department has commissioned the National Institute for Health and Care Excellence to produce clinical guidance by October 2019, which will update and replace the interim advice.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-15T12:47:21.367Zmore like thismore than 2018-11-15T12:47:21.367Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
478
label Biography information for Lord Field of Birkenhead more like this